In this sense, a recent publication based on The Cancer Genome Atlas data for cancer-predisposing variants described the detection of two MSH2 carriers among 255 unselected patients with sarcoma and the classification of MSH2 as potentially associated with sarcoma risk according to variant burden analysis (odds ratio, 9.9; p = 0.02; false discovery rate, 0.09) [37]. This evidence concerns the gene MSH2 and cancer.